Granules India shares surge over 3% after net profit surges 59% in June quarter

Shares of Granules India, the country's leading pharmaceutical manufacturing company, surged as much as 3.24% to hit an intraday high of ₹904.50 on the National Stock Exchange (NSE) on Tuesday July 21, after the company reported its April-June period earnings. On the BSE, Granules India shares advanced as much as 3.27% to touch an intraday high of ₹904.65.

Granules India in an exchange filing said that it earned a consolidated net profit of ₹180 crore in the first quarter of current financial year, marking an increase of 59% from ₹113 crore in the same period last year.

Granules India's revenue from operations during the quarter rose 22% to ₹1,477 crore from ₹1,210 crore in the year-ago period.

The company reported a strong operational performance as its earnings before interest, taxes, depreciation, and amortization (EBITDA) advanced 37% to ₹339 crore and its EBITDA margin improved by 250 basis points to 22.94%.

“Our focus remains firmly on regulatory and quality excellence, portfolio transformation toward complex and differentiated products, geographic and customer diversification and scaling new growth engines. While external cost pressures and supply chain volatility require continuous management for next couple of quarters, we are continuing to invest in R&D largely towards Complex Gx, digitalization, operational excellence, sustainability and talent to support long-term value creation. With a stronger organization, a more balanced portfolio and clear strategic priorities, we remain confident in Granules’ ability to deliver sustainable growth for all stakeholders," said Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India.

Granules India said that its revenue shares from North America at the end of first quarter came in at 72% compared with 77% in Q1FY26 but its revenue share from Europe improved to 16% from 13%.

Finished dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides CDMO contribute 74%, 13%, 9% and 4% of revenue from operations respectively for Q1FY27.

The company’s net debt stood at ₹101 crore, a reduction of ₹84.67 crore from Q1FY26 and net debt to EBITDA came in at 0.07 times.

As of 12:42 pm, Granules India shares traded 0.2% lower at ₹874 as traders booked profits at intraday high levels.